Searching across hundreds of databases
Lung cancer is one of the most common types of cancer and has a high mortality rate, worldwide. The major histopathological subtype is non‑small cell lung cancer (NSCLC). The aim of the present study was to investigate the role of long non‑coding (lnc) RNA PITPNA antisense RNA 1 (PITPNA‑AS1) in NSCLC and elucidate its potential mechanisms. The expression of PITPNA‑AS1 was determined in several NSCLC cell lines. Following PITPNA‑AS1‑silencing, cell proliferation, invasion and migration were evaluated using Cell Counting Kit‑8, colony formation, Transwell assay and wound healing assays, respectively. The expression levels of proliferation‑, migration‑ and epithelial‑mesenchymal transition (EMT)‑associated proteins were examined using immunofluorescence assay or western blot analysis. A luciferase reporter assay was conducted to verify the potential interaction between PITPNA‑AS1 and microRNA(miR)‑32‑5p. Subsequently, rescue assays were performed to investigate the effects of PITPNA‑AS1 and miR‑32‑5p on NSCLC progression. The results demonstrated that PITPNA‑AS1 was highly expressed in NSCLC tissues and cell lines. It was found that PITPNA‑AS1 silencing inhibited the proliferation, invasion and migration of NSCLC cells. Furthermore, the protein expression of E‑cadherin was upregulated, while the expression levels N‑cadherin and vimentin were downregulated. The luciferase reporter assay confirmed that miR‑32‑5p was a direct target of PITPNA‑AS1. The rescue experiments suggested that a miR‑32‑5p inhibitor significantly reversed the inhibitory effects of PITPNA‑AS1 silencing on proliferation, invasion, migration and EMT in NSCLC cells. Collectively, the present results demonstrated that PITPNA‑AS1 silencing could suppress the progression of NSCLC by targeting miR‑32‑5p, suggesting a promising biomarker in NSCLC diagnosis and treatment.
Pubmed ID: 33495838 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.
View all literature mentionsCommercial instrument and chemical vendor. Developer and manufacturer of specialized technological products for life science research and clinical diagnostics markets.
View all literature mentionsWeb application and database for analyzing cancer transcriptome data. It also has applications is facilitating tumor subgroup gene expression and survival analyses.
View all literature mentionsCell line NCI-H1299 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line A-549 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line HCC827 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line NCI-H1650 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
